Nectero Therapeutics
PrivateLast Round
Series D
Apr 11, 2024
Est. Valuation
$170M
Total Funding Raised
$211.5M
Company Overview
Nectero Therapeutics is a clinical-stage biotechnology company developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nectero Therapeutics Comparables
Compare Nectero Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shape Memory Medical | 75% | |
| Taurus Vascular | 73% | |
| W. L. Gore & Associates | 73% |
Nectero Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Apr 11, 2024 | ||||
| Series D | Jan 18, 2024 | ||||
| Series C | Sep 10, 2021 | ||||
| Series B | Apr 30, 2020 |
Nectero Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aphelion Capital | Series D |
| Cadence MedTech Ventures | Series D |
| Cadence Healthcare Ventures | Series D |
| Norwest Venture Partners | Series D |
| Boston Scientific Corporation | Series D, Series C |
| BioStar Capital | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 10, 2021
$20M round led by Boston Scientific Corporation and Cortex, Inc.
Nectero Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nectero Therapeutics's valuation, stock price, and market status.
Is Nectero Therapeutics a public or private company?
Nectero Therapeutics is a private company.
What is the current stock price of Nectero Therapeutics?
Nectero Therapeutics is a private company, so its shares have no public market price. Caplight tracks Nectero Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nectero Therapeutics worth (valuation)?
Nectero Therapeutics's valuation is estimated at $170.0M based on funding round data.
Can I buy Nectero Therapeutics stock?
Nectero Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nectero Therapeutics's last funding round?
Nectero Therapeutics's most recent funding round was Series D on April 11, 2024.
Who are the main investors in Nectero Therapeutics?
Key investors in Nectero Therapeutics include Norwest Venture Partners, Boston Scientific Corporation.
Will Nectero Therapeutics IPO soon?
No public IPO plans have been announced for Nectero Therapeutics.
How can I track Nectero Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Nectero Therapeutics's shares on secondary markets.